A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety‐net hospital

• Published in: Journal of viral hepatitis Vol. 31; no. 4; pp. 176 - 180
• Main Authors: Frye, Krysta, Davis, Andrew, Darby, Rapheisha, McDaniel, Kathryn, Quairoli, Kristi, Liu, Zhanxu, Miller, Lesley S., Fluker, Shelly‐Ann
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2024
• Subjects: chronic disease; COVID-19; Health care access; Hepatitis C; Pandemics; Patients; Primary care; Telemedicine; urban population; vulnerable populations; telemedicine; urban population; vulnerable populations; chronic disease; hepatitis C
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13913

Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care‐based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID‐19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre‐pandemic) and March 2020 to February 2021 (pandemic). Charts were ed for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre‐pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention‐to‐treat (ITT) analysis for all patients who took at least one dose of a direct‐acting antiviral (DAA) regardless of therapy completion, and a per‐protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre‐pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.